180 related articles for article (PubMed ID: 28540896)
41. Malignancy after transplantation.
Buell JF; Gross TG; Woodle ES
Transplantation; 2005 Oct; 80(2 Suppl):S254-64. PubMed ID: 16251858
[TBL] [Abstract][Full Text] [Related]
42. Kaposi's sarcoma in kidney transplant recipients: a 23-year experience.
Moosa MR
QJM; 2005 Mar; 98(3):205-14. PubMed ID: 15728402
[TBL] [Abstract][Full Text] [Related]
43. Malignancy after renal transplantation: a single-center experience.
Vrotniakaite K; Jaceviciute R; Rudminiene I; Laucyte-Cibulskiene A; Rainiene T; Jankevicius F; Zelvys A; Miglinas M
Ann Transplant; 2014 Sep; 19():456-63. PubMed ID: 25223375
[TBL] [Abstract][Full Text] [Related]
44. Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience.
Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
Clin Exp Nephrol; 2007 Jun; 11(2):151-155. PubMed ID: 17593515
[TBL] [Abstract][Full Text] [Related]
45. Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant.
Elmagd MM; Bakr MA; Metwally AH; Wahab AM
Exp Clin Transplant; 2008 Mar; 6(1):42-7. PubMed ID: 18405244
[TBL] [Abstract][Full Text] [Related]
46. Comparative analysis of azathioprine versus cyclosporine-based therapy in primary haplo-identical live-donor kidney transplantation: a 20-year experience.
Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
Saudi J Kidney Dis Transpl; 2008 Jul; 19(4):564-70. PubMed ID: 18580014
[TBL] [Abstract][Full Text] [Related]
47. Posttransplantation lymphoproliferative disorders in renal transplant recipients: report of over 20 years of experience.
Saadat A; Einollahi B; Ahmadzad-Asl MA; Moradi M; Nafar M; Pourfarziani V; Firoozan A; Porrezagholi F; Davoudi F
Transplant Proc; 2007 May; 39(4):1071-3. PubMed ID: 17524894
[TBL] [Abstract][Full Text] [Related]
48. The incidence of tumours in renal transplant recipients with long-term immunosuppressive therapy.
Ondrus D; Pribylincová V; Breza J; Bujdák P; Miklosi M; Reznícek J; Zvara V
Int Urol Nephrol; 1999; 31(4):417-22. PubMed ID: 10668934
[TBL] [Abstract][Full Text] [Related]
49. Post-renal transplant malignancies: Opportunities for prevention and early screening.
Turshudzhyan A
Cancer Treat Res Commun; 2021; 26():100283. PubMed ID: 33338850
[TBL] [Abstract][Full Text] [Related]
50. Posttransplant Kaposi's sarcoma: report from a single center.
Huang JY; Chiang YJ; Lai PC; Shih LY; Huang CC; Chu SH; Wu CH
Transplant Proc; 2004 Sep; 36(7):2145-7. PubMed ID: 15518778
[TBL] [Abstract][Full Text] [Related]
51. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases.
Baccarani U; Adani GL; Montanaro D; Risaliti A; Lorenzin D; Avellini C; Tulissi P; Groppuzzo M; Currò G; Luvisetto F; Beltrami A; Bresadola V; Viale PL; Bresadola F
Transplant Proc; 2006 May; 38(4):1135-7. PubMed ID: 16757287
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma.
Gutiérrez-Dalmau A; Sánchez-Fructuoso A; Sanz-Guajardo A; Mazuecos A; Franco A; Rial MC; Iranzo P; Torregrosa JV; Oppenheimer F; Campistol JM
Transplant Proc; 2005 Nov; 37(9):3836-8. PubMed ID: 16386556
[TBL] [Abstract][Full Text] [Related]
53. Posttransplant Lymphoproliferative Disorder in Kidney and Liver Transplant Recipients: A Single-Center Experience.
Wójciak M; Gozdowska J; Dęborska-Materkowska D; Perkowska-Ptasińska A; Kosieradzki M; Nazarewski S; Durlik M
Transplant Proc; 2018 Sep; 50(7):2154-2158. PubMed ID: 30177129
[TBL] [Abstract][Full Text] [Related]
54. Potent immunosuppression for ABO-incompatible renal transplantation may not be a risk factor for malignancy.
Yamamoto T; Kawaguchi T; Watarai Y; Tujita M; Hiramitsu T; Nanmoku K; Goto N; Katayama A; Kobayashi T; Uchida K
Transplant Proc; 2012 Jan; 44(1):210-3. PubMed ID: 22310616
[TBL] [Abstract][Full Text] [Related]
55. Optimizing Immunosuppressive Regimens Among Living-Donor Renal Transplant Recipients.
Bakr MA; Nagib AM; Gheith OA; Hamdy AF; Refaie AF; Donia AF; Neamatalla AH; Eldahshan KF; Denewar AA; Abbas MH; Mostafa AI; Ghoneim MA
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):16-23. PubMed ID: 28260425
[TBL] [Abstract][Full Text] [Related]
56. De novo malignancies in renal transplant recipients: experience at a single center with 1882 transplant patients over 39 yr.
Apel H; Walschburger-Zorn K; Häberle L; Wach S; Engehausen DG; Wullich B
Clin Transplant; 2013; 27(1):E30-6. PubMed ID: 23278453
[TBL] [Abstract][Full Text] [Related]
57. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009.
Piselli P; Serraino D; Segoloni GP; Sandrini S; Piredda GB; Scolari MP; Rigotti P; Busnach G; Messa P; Donati D; Schena FP; Maresca MC; Tisone G; Veroux M; Sparacino V; Pisani F; Citterio F;
Eur J Cancer; 2013 Jan; 49(2):336-44. PubMed ID: 23062667
[TBL] [Abstract][Full Text] [Related]
58. Malignancy after kidney transplantation: results of 400 patients from a single center.
Stratta P; Morellini V; Musetti C; Turello E; Palmieri D; Lazzarich E; Cena T; Magnani C
Clin Transplant; 2008; 22(4):424-7. PubMed ID: 18312442
[TBL] [Abstract][Full Text] [Related]
59. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients.
Morton M; Coupes B; Roberts SA; Klapper PE; Byers RJ; Vallely PJ; Ryan K; Picton ML
Transplantation; 2013 Feb; 95(3):470-8. PubMed ID: 23222821
[TBL] [Abstract][Full Text] [Related]
60. [Cancer after kidney transplantation].
Sandrini S; Setti G; Bossini N; Maiorca P
G Ital Nefrol; 2004; 21 Suppl 26():S67-73. PubMed ID: 15732048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
